Loading
Endoplasmic Reticulum Stress and Disease · Journal article
Autophagy · August 17, 2026
Encouraging direction, but not yet definitive.
This study develops a transcriptome-based framework linking macroautophagy (MA) and chaperone-mediated autophagy (CMA) states to drug sensitivity and identifies CMA suppression, achievable with ATRA, as a mechanism to enhance EGFR-TKI sensitivity in KRAS-mutant pancreatic cancer cells and xenografts. The mechanism involves SEMA6D downregulation and increased MA flux, with ATRA showing efficacy in vivo without significant toxicity.
Transcriptomic integrative analysis coupled with mechanistic cell and xenograft studies. In vitro: KRAS-mutant pancreatic cancer cell lines (pooled analysis across multiple cancer cell lines for transcriptomic framework). In vivo: PANC-1 xenografts (pancreatic cancer).. Intervention: LAMP2A genetic depletion, all-trans retinoic acid (ATRA), SEMA6D depletion, EGFR-TKI; combination ATRA + EGFR-TKI. Compared with: Untreated controls, EGFR-TKI alone, ATRA alone.
MAhigh CMAhigh states were associated with relative resistance to EGFR-TKIs, whereas MAhigh CMAlow states showed greater sensitivity in pooled cancer cell-line analyses LAMP2A depletion enhanced sensitivity to EGFR-TKIs in an MA-dependent manner in KRAS-mutant pancreatic cancer cells ATRA phenocopied genetic CMA suppression and potentiated sensitivity to EGFR-TKIs
Xenograft study lacked explicit control arms and toxicity metrics beyond 'without significant toxicity' In PANC-1 xenografts, ATRA potentiated EGFR-TKI-mediated tumor suppression without significant toxicity
These results suggest CMA suppression as a rational approach to overcome EGFR-TKI resistance in KRAS-mutant pancreatic cancer. ATRA is a well-characterized retinoid available clinically; the findings provide mechanistic rationale for testing the ATRA + EGFR-TKI combination in pancreatic cancer patients, but clinical validation is needed.
A sound but single-cancer-model mechanistic study with cell-line and xenograft data, identifying a druggable autophagy-CMA pathway in KRAS-mutant pancreatic cancer; needs confirmation in clinical trials.
As stated by the source record.
Quoted from the source exactly as published.
These results suggest CMA suppression as a rational approach to overcome EGFR-TKI resistance in KRAS-mutant pancreatic cancer. ATRA is a well-characterized retinoid available clinically; the findings provide mechanistic rationale for testing the ATRA + EGFR-TKI combination in pancreatic cancer patients, but clinical validation is needed.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Macroautophagy (MA) and chaperone-mediated autophagy (CMA) are lysosomal degradation pathways with context-dependent roles in cancer. However, how MA- and CMA-associated transcriptional states jointly relate to cancer molecular features and drug responses remains unclear. Here, we developed a transcriptome-based framework integrating MA- and CMA-associated gene signatures to define relative MA and CMA states across cancer types. These states were associated with distinct patterns of genomic instability, oncogenic signaling, immune features, and pharmacogenomic profiles. In pooled cancer cell-line analyses, MAhigh CMAhigh states were associated with relative resistance to EGFR tyrosine kinase inhibitors (EGFR-TKIs), whereas MAhigh CMAlow states showed greater sensitivity, nominating an autophagy-associated pharmacological pattern for mechanistic investigation. Using KRAS-mutant pancreatic cancer cells as an autophagy-dependent, therapy-resistant model, we found that LAMP2A depletion enhanced sensitivity to EGFR-TKIs in an MA-dependent manner. All-trans retinoic acid (ATRA), a pleiotropic retinoid that modulated CMA-related activity in this system, phenocopied key effects of genetic CMA suppression and potentiated sensitivity to EGFR-TKIs. CMA suppression was associated with increased autophagic flux, TFEB nuclear localization, and ULK1 phosphorylation changes consistent with MA activation. Moreover, transcriptomic analysis reveals that CMA suppression sensitizes cancer cells to EGFR-TKIs at least partially through downregulation of SEMA6D. SEMA6D depletion enhanced autophagic flux, increased lysosomal capacity, and partially contributed to the response to combined EGFR-TKI and ATRA treatment. In PANC-1 xenografts, ATRA potentiated EGFR-TKI-mediated tumor suppression without significant toxicity. Together, these findings establish a transcriptome-based MA-CMA framework for prioritizing context-dependent autophagy-associated vulnerabilities and provide focused mechanistic support for MA-CMA crosstalk in KRAS-mutant pancreatic cancer models.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.